Accueil > Microbiologie & Sciences Humaines > Les équipes de recherche > Equipe n°8: Bruno Pradines, PharmD, PhD

Microbiologie & Sciences Humaines

Equipe n°8: Bruno Pradines, PharmD, PhD

Maladies tropicales émergentes

 

 

1. Team composition

 

 

  1. Bruno PRADINES- PharmD-PhD, Responsable de spécialité mention recherche du Service de santé des armées, HDR.
  2. Christophe ROGIER - PR1, Professeur agrégé de recherche du Service de santé des armées, MD-PhD, HDR.
  3. Leonardo BASCO - DR2-IRD, MD-PhD, HDR.
  4. Bruno POUVELLE - IR Université, PhD, HDR.
  5. Sébastien BRIOLANT – MD-PhD, Praticien certifié du Service de santé des armées en Biologie et Biochimie des Agressions.
  6. Lionel ALMERAS - PhD, Agent sous contrat titularisable du Service de santé des armées.
  7. Hervé BOGREAU – PhD, Agent sous contrat titularisable du Service de santé des armées.

 

2. Achievements

 Scientific output

In 2013 at the closure of the Marseilles site of the Institut de Recherche Biomédicale des Armées, the team 8 was restructured into 5 sites (Equipe Résidente de Recherche en Infectiologie Tropicale, HIA Laveran, Marseille; Faculté de Médecine, Aix-Marseille2; Faculté d’Orsay, IRD, Orsay; Direction interarmées du Service de santé en Guyane et Institut Pasteur de Guyane, Cayenne; Unité de parasitologie, Institut de Recherche Biomédicale des Armées, Brétigny sur Orge). This restructuring was marked by the departure of Christophe Rogier and Eric Barret in 2011, Aurélie Pascual and Nathalie Wurtz in 2012, Lionel Almeras and Dominique Travers in 2013, Housem Bouchiba in 2016, the death of Julien Cren in 2014 and the integration of Marylin Madamet and Nicolas Benoit in 2013, Lionel Almeras, Christophe Nguyen and Joel Mosnier in 2016. In September 2016, the team 8 will be restructured again but in a unique team in the Institut Hospitalo-universitaire d’Infectiologie in Marseille.

                In team 8, seven main themes have been developed. Five of these main themes focused on malaria infections: 1) Improvement of laboratory diagnosis of malarial infections with development of rapid and accurate alternative laboratory tools, 2) Active surveillance and monitoring of temporal trends in parasite susceptibility of P. falciparum and P. vivax, 3) Identification and development of new molecular markers of antimalarial resistance, 4) Development of new antimalarial drugs (in vitro and in vivo) with evaluation and investigation of mode of action of new antimalarial drugs and mechanisms of resistance, 5) Mosquito-human interactions (development of serological method based on antibody response against salivary proteins from vectors, development of new tools for vector identification and surveillance of vector populations), 6) Compliance with antimalarial chemoprophylaxis and anti-vectorial protective measures, 7) Surveillance of vector borne diseases in French Guiana.

 

1)      Improvement of laboratory diagnosis of malarial infections with development of rapid and accurate alternative laboratory tools

                One of our missions for the army and for the national referent center of malaria is the validation of new alternative diagnostic tools (1). In cases where microscopic examination cannot be performed, rapid diagnostic tests (RDT) are recommended by the World Health Organization. Most products target the Plasmodium falciparum histidine-rich protein 2 (HRP2). The team showed that pfhrp2 sequence variations, particularly with regard to certain amino acid repeats, can affect the sensitivity of HRP2-based RDT (2,3). In addition, misdiagnosis may also arise from pfhrp2 gene deletions hat prevent the expression of proteins by the parasites and were reported as the cause of false-negative diagnoses (2).

The detection of parasites and the control of the malaria disease become difficult in areas of low and unstable transmission where malaria is in pre-elimination stage. Serological tools can be used to assess the transmission level and thus the prevalence of P. falciparum and P. vivax in human populations and to assess epidemiological facts of the past and present. We validated these serological tools in the Republic of Djibouti, where French soldiers stayed, and evaluated the prevalence rate of P. falciparum, P. vivax and mixed infections in Djiboutian population (4).

 

2)     Active surveillance and monitoring of temporal trends in parasite susceptibility of P. falciparum and P. vivax

a. Active surveillance of imported malaria and parasite susceptibility to antimalarial drugs

Since 2008, the unit of parasitology has been involved as laboratory associated to the national referent center of malaria (CNR paludisme). We conducted epidemiological and clinical analyses of imported malaria cases (5-8). In addition, we evaluate the in vitro susceptibility of P. falciparum parasites (ex vivo and molecular markers) and clinical efficacy in patients (travelers and soldiers) to adapt chemoprophylaxis and malaria treatment and control strategies in French armed forces and in civilian recommendations (9-19).

b.       Active surveillance of malaria in French endemic malaria areas and parasite susceptibility to antimalarial drugs (French Guiana and Mayotte)

Like for imported malaria, we conducted epidemiological, clinical analyses and antimalarial resistance studies on malaria cases from soldiers, travelers or illegal miners from French Guiana or residents of Mayotte (20-24)

c.  Active surveillance of malaria in endemic areas and parasite susceptibility to antimalarial drugs

Epidemiological studies on P. falciparum and P. vivax and evaluation of clinical efficacy and in vitro resistance (ex vivo and molecular markers) were conducted in malaria endemic areas where French soldiers are staying or could stay in future, like Ivory Coast, Republic of Central Africa, Senegal, Gabon, Congo, Djibouti, Mauritania, Congo, Cameroon, Mali, Madagascar (25-69).

3)     Identification and development of new molecular markers of antimalarial resistance

                The resistance of malaria to most antimalarial drugs has developed in Southeast Asia and has spread to Africa. The World Health Organization (WHO) has recommended artemisinin-based combination therapy (ACT) as the first-line treatment for malaria since 2005. As recently described in Southeast Asia, the emergence of P. falciparum resistance to artemisinin and its derivatives manifests as delayed parasite clearance following treatment with either artesunate monotherapy or ACT. In areas where artemisinin resistance is emerging, the partner drugs within the combination are under increasing pressure for the selection of resistance. In this context, the identification of molecular markers of resistance to these partner drugs is urgently needed for monitoring the emergence and spread of resistance to antimalarial drugs. We participate in identification, development and/or validation of new molecular markers of resistance to doxycycline (pfmdt and pftetQ) (70-76), quinine (pfnhe-1) (77-79), artemisinin (K13) (24,60,62,68,80) and quinolines (pfmdr1, pfmdr2, pfmdr5, pfmdr6…) (81-86).

4)      Development of new antimalarial drugs (in vitro and in vivo) with evaluation and investigation of mode of action of new antimalarial drugs and mechanisms of resistance

                The team 8 participates in the identification of new antimalarial drugs by in vitro screening in collaboration with several international departments of medical chemistry (87-95) and in the development of potential antimalarial drugs like ferroquine (96), cepharantine (97-99), atorvastatin (100-103) and methylene blue (104-107), in collaboration with international pharmaceutical laboratories. The development of these antimalarial drugs is based on evaluation of in vitro activity against P. falciparum clones, evaluation of ex vivo activity against P. falciparum field isolates from several areas, evaluation of in vivo activity in experimental models (uncomplicated malaria and cerebral malaria), and identification of the mode of action and potential mechanisms of resistance.

5)      Mosquito-human interactions

 a. Development of serological method based on antibody response against salivary proteins from vectors

We developed tools to evaluate the risks of exposure of soldiers to vector bites by identification of biomarkers of exposure by analyzing of mosquitoes or ticks salivary antigenic proteins and serological responses associated with the level of exposure (108-115). These tools allowed evaluate the effectiveness of anti-vectorial strategies, estimate the risk of disease transmission and monitor mosquito populations (116-117).

 b. Development of new tools for vector identification and surveillance of vector populations

                Arthropod species including tick and mosquito vectors can be morphologically identified using taxonomic keys for endemic species in several geographic regions. However, morphological identification can be difficult because it requires some entomological expertise, and it is difficult to identify a specimen that is damaged or at an immature stage of its life cycle. Molecular methods, have been developed to identify arthropods (particularly in French Guiana).


 c. Entomological investigations and evaluation of control strategies

Vector-borne diseases constitute a threat to the operational capacity of armed forces personnel operating outside or stationed overseas. We participated in the monitoring of entomological status of French military bases in sub-saharan Africa (Gabon, Ivory Coast, Republic of Central Africa, Senegal, Djibouti) and French Guiana (118-120). This surveillance is based on identification of vectors, study of behavior and evaluation of insecticide resistance. The team created the Impact Vector project which aimed was to evaluate the vector-borne disease risks for troops in combat situations. The team also contributes by its expertise to the investigation of epidemic disease, and participates in the development of a global strategy for vector-control for the armed services. Additionally, we participate in the evaluation of antivectorial control programs in several areas in collaboration with oversea civilians units of entomology (121-126).

 

d. Prediction of malaria transmission

We showed that the use of remotely sensed environmental and meteorological data allows to predict the risk of malaria transmission in Africa (127-129)

 

6)      Compliance with antimalarial chemoprophylaxis and anti-vectorial protective measures

                Drug resistance is based on a body of clinical and scientific arguments. Poor compliance (insufficient oversight or intolerance) and under-dosing (insufficient dosage, poor absorption, drug interactions or defects in drug metabolism) may also contribute to prophylactic or clinical failure. It is important to evaluate the compliance in French troops or in travellers and to determine the determinants of non-compliance to improve recommendations and strategies (130-131). These studies were conducted in collaboration with the CESPA (Centre d’épidémiologie et de santé publique des armées, Marseille).

 

References for URMITE - Team 8 2011 - 2015

Improvement of laboratory diagnosis of malarial infections with development of rapid and accurate alternative laboratory tools

  1. Tahar R, Sayang C, Ngane Foumane V, Soula G, Moyou-Somo R, Delmont J, Basco LK. Field evaluation of rapid diagnostic tests for malaria in Yaounde, Cameroon. Acta Trop. 2013;125:214-9.
  2. Wurtz N, Fall B, Bui K, Pascual A, Fall M, Camara C, Diatta B, Ba Fall K, Saliou Mbaye P, Diémé Y, Bercion R, Wade B, Briolant S, Pradines B. Pfhrp2 and pfhrp3 polymorphisms in Plasmodium falciparum isolates from Dakar, Senegal: Impact on rapid malaria diagnostic tests. Malar J. 2013;12:34.
  3. Wurtz N, Briolant S, Lemarié D, Pommier De Santi V, Pascual A, Roodt T, Benoit N, Hupin C, Pradines B. Retard de diagnostic d'un accès palustre à Plasmodium falciparum chez un militaire en Ouganda : négativité des tests de diagnostic rapide associée à un polymorphisme de l'antigène HRP2. Med Sante Trop. 2013;23:181-4.
  4. Khaired BA, Briolant S, Pascual A, Mokrane M, Machault V, Travaillé C, Khaired MA, Farah MA, Ali HM, Abdi AI, Ayeh SN, Darar HY, Ollivier L, Waiss MK, Bogreau H, Rogier C, Pradines B. Plasmodium vivax and Plasmodium falciparum infections in the Republic of Djibouti: evaluation of their prevalence and potential determinants. Malar J. 2012;11:395.

 

Active surveillance of imported malaria and parasite susceptibility to antimalarial drugs

5. Vareil MO, Tandonnet O, Chemoul A, Bogreau H, Saint-Léger M, Micheau M, Millet P, Koeck JL, Boyer A, Rogier C, Malvy D. Unusual transmission of Plasmodium falciparum, Bordeaux, France, 2009. Emerg Infect Dis. 2011;17:248-50.

6. Rogier C. Soldiers and epidemics. Clin Microbiol Infect. 2012;18:721-2.

7. De Laval F, Simon F, Bogreau H, Rapp C, Wurtz N, Oliver M, Demaison X, Dia A, De Pina JJ, Merens A, Migliani R. Emergence of Plasmodium ovale malaria among the French armed forces in the Republic of Ivory Coast: 20 years of clinical and biological experiences. Clin Infect Dis. 2014;58:122-8.

8. Javelle E, Madamet M, Gaillard T, Velut G, Surcouf C, Michel R, Garnotel E, Simon F, Pradines B. Delayed P. falciparum malaria after doxycycline prophylaxis, Central African Republic. Antimicrob Agents Chemother. 2016;60:2592-3.

9. Pradines B, Bertaux L, Pomares C, Delaunay P, Marty P. Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia. Malar J. 2011;18;10:268.

10. Pascual A, Parola P, Benoit-Vical F, Simon F, Malvy D, Picot S, Delaunay P, Basset D, Maubon D, Faugere B, Menard G, Bourgeois N, Oeuvray C, Didillon E, Rogier C, Pradines B. Ex vivo activity of the ACT new compounds pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum. Malar J. 2012;11:45.

11. Wurtz N, Pascual A, Marin-Jauffre A, Bouchiba H, Benoit N, Desbordes M, Martelloni M, Pommier De Santi V, Richa G, Taudon N, Pradines B, Briolant S. Early treatment failure during tratment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast. Malar J. 2012;11:146.

12. Gharbi M, Pillai DR, Lau R, Hubert V, Khaimar K, Existe A, Kendjo A, Dahlstrom S, Guérin PJ, Le Bras J, Members Of The French National Reference Center For Imported Malaria Study. Chloroquine-resistance malaria in travellers returning from Haiti after 2010 Earthquake. Emerg Infect Dis. 2012;18:1346-9.

13. Gharbi M, Flegg Ja, Hubert V, Kendjo E, Metcalf Je, Bertaux L, Guérin Pj, Le Bras J; Members Of The French National Reference Centre For Imported Malaria Study, Aboubaca A, Agnamey P, Angoulvant A, Barbut P, Basset D, Belkadi G, Bellanger Ap, Bemba D, Benoit-Vica F, Berry A, Bigel Ml, Bonhomme J, Botterel F, Bouchaud O, Bougnoux Me, Bourée P, Bourgeois N, Branger C, Bret L, Buret B, Casalino E, Chevrier S, Conquere De Monbrison F, Cuisenier B, Danis M, Darde Ml, De Gentile L, Delarbre Jm, Delaunay P, Delaval A, Desoubeaux G, Develoux M, Dunand J, Durand R, Eloy O, Fauchet N, Faugere B, Faye A, Fenneteau O, Flori P, Fontrouge M, Garabedian C, Gayandrieu F, Godineau N, Houzé P, Houzé S, Hurst Jp, Ichou H, Lachaud L, Lebuisson A, Lefevre M, Leguern As, Le Moal G, Lusina D, Machouart Mc, Malvy D, Matheron S, Maubon D, Mechali D, Megarbane B, Menard G, Millon L, Aiach Mm, Minodier P, Morelle C, Nevez G, Parola P, Parzy D, Patey O, Patoz P, Penn P, Perignon A, Picot S, Pilo Je, Poilane I, Pons D, Poupart M, Pradines B, Raffenot D, Rapp C, Receveur Mc, Sarfati C, Senghor Y, Simon F, Siriez Jy, Taudon N, Thellier M, Thouvenin M, Toubas D. Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000-2011. Malar J. 2013;12:35.

14. Woodrow C, Dahlström S, Cooksey R, Flegg JA, Le Nagard H, Mentre F, Murillo C, Menard D, Nosten F, Sriprawat K, Musset L, Quashie NB, Lim P, Fairhurst RM, Nsobya SL, Sinou V, Noedl H, Pradines B, Johnson JD, Guerin PJ, Sibley C, Le Bras J. High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool. Antimicrob Agents Chemother. 2013;57:3121-30.

15. Gharbi M, Flegg JA, Pradines B, Berenger A, Ndiaye M, Djimde AA, Roper C, Hubert V, Kendjo E, Venkatesan M, Brasseur P, Gaye O, Offianan AT, Penali L, Le Bras J, Guerin PJ. Surveillance of travellers: An additional tool for tracking antimalarial drug resistance in endemic countries. PlosOne 201; 8:77775.

16. Migliani R, Pradines B, Michel R, Aoun O, Dia A, Deparis X, Rapp C. Malaria control strategies in French armed forces. Trav Med Infect Dis. 2014;12:307-17.

17. Pascual A, Madamet M, Briolant S, Gaillard T, Amalvict R, Benoit N, Travers D, Pradines B and the French National Reference Centre for Imported Malaria Study Group. Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine. Malar J. 2015;14 :49.

18. Madamet M, Gaillard T, Velut G, Ficko C, Houze P, Bylicki C, Merat S, Houze S, Taudon N, Michel R, Pasquier P, Rapp C, Pradines B. Malaria prophylaxis failure with doxycycline, Central African Republic, 2014. Emerg Infect Dis. 2015;21:1485-6.

19. Rapp C, Simon F, Pradines B. Prévention du paludisme d’importation en France métropolitaine. Actualité et Dossier en Santé Publique. 2011 ;76 :36-9.

 

Active surveillance of malaria in French endemic malaria areas and parasite susceptibility to antimalarial drugs (French Guiana and Mayotte)

20. Bertaux L, Kraemer P, Taudon N, Trignol A, Martelloni M, Saidi R, Parzy D, Pradines B, Simon F. Quinine-resistant malaria in traveler returning from French Guiana, 2010. Emerg Infect Dis. 2011;17:943-5.

21. Pommier De Santi V, Dia A, Adde A, Hyvert G, Galant J, Mazevet M, Nguyen C, Vezenegho Sb, Dusfour I, Girod R, Briolant S. Malaria in French Guiana linked to illegal gold mining. Emerg Infect Dis. 2016;22:344-6.

22. Pommier De Santi V, Girod R, Mura M, Dia A, Briolant S, Djossou F, Dusfour I, Mendibil A, Simon F, Deparis X, Pagès F. Epidemiological and entomological studies of a malaria outbreak among French armed forces deployed at illegal gold mining sites reveal new aspects of the disease’s transmission in French Guiana. Malar J. 2016 ;15:35.

23. Pommier De Santi V, Djossou Fc, Barthes N, Bogreau H, Hyvert G, Nguyen C, Pelleau Sc, Legrand E, Musset L, Nacher M, Briolant S. Malaria hyperendemicity and risk for artemisinin resistance among illegal gold miners, French Guiana. Emerg Infect Dis. 2016;22:903-6.

24. Torrentino-Madamet M, Collet L, Lepère J F, Benoit N, Amalvict R, Ménard D, Pradines B. K13-propeller polymorphisms in Plasmodium falciparum isolated in Mayotte in 2013. Antimicrob. Agents Chemother. 2015;59:7878-80.

 

Active surveillance of malaria in endemic areas and parasite susceptibility to antimalarial drugs

25. Mint Lekweiry K, Ould Mohamed Salem Boukhary A, Gaillard T, Wurtz N, Bogreau H, Hafid JE, Trape JF, Bouchiba H, Ould Ahmedou Salem MS, Pradines B, Rogier C, Basco LK, Briolant S. Molecular surveillance of drug-resistant Plasmodium vivax using pvdhfr, pvdhps and pvmdr1 markers in Nouakchott, Mauritania. J Antimicrob Chemother. 2012;67:367-74.

26. Wurtz N, Mint Lekweiry K, Bogreau H, Pradines B, Rogier C, Ould Mohamed Salem Boukhary A, Hafid JE, Ould Ahmedou Salem MS, Trape JF, Basco LK, Briolant S. Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malar J. 2011;10:336.

27. Lekweiry KM, Basco LK, Salem MS, Hafid JE, Marin-Jauffre A, Weddih AO, Briolant S, Bogreau H, Pradines B, Rogier C, Trape JF, Boukhary AO. Malaria prevalence and morbidity among children reporting at health facilities in Nouakchott, Mauritania. Trans R Soc Trop Med Hyg. 2011;105:727-33.

28. Fall B, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbaye PS, Fall F, Diémé Y, Rogier C, Wade B, Bercion R, Pradines B. Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Malar J. 2011;10:310.

29. Robert V, Trape JF, Rogier C. Malaria parasites: elimination is not eradication. Clin Microbiol Infect. 2011;17:1597-9.

30. Dicko A, Toure SO, Traore M, Sagara I, Toure OB, Sissoko MS, Diallo AT, Rogier C, Salomon R, de Sousa A, Doumbo OK. Increase in EPI vaccines coverage after implementation of intermittent preventive treatment of malaria in infant with Sulfadoxine -pyrimethamine in the district of Kolokani, Mali: results from a cluster randomized control trial. BMC Public Health. 2011;11:573.

31. Tahar R, Albergaria C, Zeghidour N, Ngane VF, Basco LK, Roussilhon C. Plasma levels of eight different mediators and their potential as biomarkers of various clinical malaria conditions in African children. Malar J. 2016;15:337.

32. Ouldabdallahi Moukah M, Ba O, Ba H, Ould Khairy ML, Faye O, Bogreau H, Simard F, Basco LK. Malaria in three epidemiological strata in Mauritania. Malar J. 2016;15(1):204.

33. Singana BP, Bogreau H, Matondo BD, Dossou-Yovo LR, Casimiro PN, Mbouka R, Ha Nguyen KY, Pradines B, Basco LK, Ndounga M. Malaria burden and anti-malarial drug efficacy in Owando, northern Congo. Malar J. 2016;15:16.

34. Ndounga M, Pembe Issamou Mayengue, Casimiro PN, Koukouikila-Koussounda F, Bitemo M, Diassivy Matondo B, Ndounga Diakou LA, Basco LK, Ntoumi F. Artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study. Malar J. 2015;14:423.

35. Abdul-Ghani R, Basco LK, Beier JC, Mahdy MA. Inclusion of gametocyte parameters in anti-malarial drug efficacy studies: filling a neglected gap needed for malaria elimination. Malar J. 2015;14:413.

36. Ould Ahmedou Salem MS, Basco LK, Ouldabdallahi M, Mint Lekweiry K, Konaté L, Faye O, Ould Mohamed Salem Boukhary A. Malaria-associated morbidity during the rainy season in Saharan and Sahelian zones in Mauritania. Acta Trop. 2015;152:1-7.

37. Foumane Ngane V, Allico Djaman J, Culeux C, Piette N, Carnevale P, Besnard P, Fortes F, Basco LK, Tahar R. Molecular epidemiology of drug-resistant Plasmodium falciparum in Benguela province, Angola. Malar J. 2015;14:113.

38. Lekweiry KM, Salem MS, Basco LK, Briolant S, Hafid J, Boukhary AO. Malaria in Mauritania: retrospective and prospective overview. Malar J. 2015;14:100.

39. Ould Ahmedou Salem MS, Mohamed Lemine YO, Deida JM, Lemrabott MA, Ouldabdallahi M, Ba MD, Boukhary AO, Khairy ML, Abdel Aziz MB, Ringwald P, Basco LK, Niang SD, Lebatt SM. Efficacy of chloroquine for the treatment of Plasmodium vivax in the Saharan zone in Mauritania. Malar J. 2015;14:39.

40. Ould Ahmedou Salem MS, Mint Lekweiry K, Mint Deida J, Ould Emouh A, Ould Weddady M, Ould Mohamed Salem Boukhary A, Basco LK. Increasing prevalence of Plasmodium vivax among febrile patients in Nouakchott, Mauritania. Am J Trop Med Hyg. 2015;92:537-40.

41. Ouldabdallahi M, Alew I, Salem MS, Dit Dialaw Ba M, Boukhary AO, Khairy ML, Aziz MB, Ringwald P, Basco LK, Niang SD, Lebatt SM. Efficacy of artesunate-amodiaquine for the treatment of acute uncomplicated falciparum malaria in southern Mauritania. Malar J. 2014;13:49

42. Almelli T, Nuel G, Bischoff E, Aubouy A, Elati M, Wang CW, Dillies MA, Coppée JY, Ayissi GN, Basco LK, Rogier C, Ndam NT, Deloron P, Tahar R. Differences in gene transcriptomic pattern of Plasmodium falciparum in children with cerebral malaria and asymptomatic carriers. PLoS One. 2014;9:114401.

43. Tahar R, Almelli T, Debue C, Foumane Ngane V, Djaman Allico J, Whegang Youdom S, Basco LK. Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children. J Infect Dis. 2014;210:1962-71.

44. Khaireh BA, Assefa A, Guessod HH, Basco LK, Khaireh MA, Pascual A, Briolant S, Bouh SM, Farah IH, Ali HM, Abdi AI, Aden MO, Abdillahi Z, Ayeh SN, Darar HY, Koeck JL, Rogier C, Pradines B, Bogreau H. Population genetics analysis during the elimination process of Plasmodium falciparum in Djibouti. Malar J. 2013;12:201.

45. Ndounga M, Mayengue PI, Casimiro PN, Loumouamou D, Basco LK, Ntoumi F, Brasseur P. Artesunate-amodiaquine efficacy in Congolese children with acute uncomplicated falciparum malaria in Brazzaville. Malar J. 2013;12:53.

46. Ndounga M, Tahar R, Casimiro PN, Loumouamou D, Basco LK. Clinical efficacy of artemether-lumefantrine in Congolese children with acute uncomplicated falciparum malaria in Brazzaville. Malar Res Treat. 2012;2012:749479.

47. Whegang Youdom S, Samson A, Basco LK, Thalabard JC. Multiple treatment comparisons in a series of anti-malarial trials with an ordinal primary outcome and repeated treatment evaluations. Malar J. 2012;11:147.

48. Menard S, Morlais I, Tahar R, Sayang C, Mayengue PI, Iriart X, Benoit-Vical F, Lemen B, Magnaval JF, Awono-Ambene P, Basco LK, Berry A. Molecular monitoring of Plasmodium falciparum drug susceptibility at the time of the introduction of artemisinin-based combination therapy in Yaoundé, Cameroon: implications for the future. Malar J. 2012;11:113.

49. Mint Lekweiry K, Ould Mohamed Salem Boukhary A, Gaillard T, Wurtz N, Bogreau H, Hafid JE, Trape JF, Bouchiba H, Ould Ahmedou Salem MS, Pradines B, Rogier C, Basco LK, Briolant S. Molecular surveillance of drug-resistant Plasmodium vivax using pvdhfr, pvdhps and pvmdr1 markers in Nouakchott, Mauritania. J Antimicrob Chemother. 2012;67:367-74.

50. Wurtz N, Mint Lekweiry K, Bogreau H, Pradines B, Rogier C, Ould Mohamed Salem Boukhary A, Hafid JE, Ould Ahmedou Salem MS, Trape JF, Basco LK, Briolant S. Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malar J. 2011;10:336.

51. Lekweiry KM, Basco LK, Salem MS, Hafid JE, Marin-Jauffre A, Weddih AO, Briolant S, Bogreau H, Pradines B, Rogier C, Trape JF, Boukhary AO. Malaria prevalence and morbidity among children reporting at health facilities in Nouakchott, Mauritania. Trans R Soc Trop Med Hyg. 2011;105:727-33.

52. Wurtz N, Fall B, Pascual A, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbaye PS, Fall F, Dieme Y, Rogier C, Bercion R, Briolant S, Wade B, Pradines B. Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal. Malar J. 2012;11:197.

53. Dorkenoo Ma, Barrette A, Agbo Ym, Bogreau H, Kutoati S, Sodahlon Yk, Morgah K. Surveillance of the efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum among children under five in Togo, 2005-2009. Malar J. 2012;11:338.

54. Dicko A, Konare M, Traore D, Testa J, Salamon R, Doumbo O, Rogier C. The implementation of malaria intermittent preventive trialtreatment with sulphadoxine-pyrimethamine in infants reduced all-cause mortality in the district of Kolokani, Mali: results from a cluster randomized control. Malar J. 2012;1: 73.

55. Yalcindag E, Elguero E, Arnathau C, Durand P, Akiana J, Anderson Tj, Aubouy A, Balloux F, Besnard P, Bogreau H, Carnevale P, D'alessandro U, Fontenille D, Gamboa D, Jombart T, Le Mire J, Leroy E, Maestre A, Mayxay M, Menard D, Musset L, Newton Pn, Nkoghe D, Noya O, Ollomo B, Rogier C, Veron V, Wide A, Zakeri S, Carme B, Legrand E, Chevillon C, Ayala Fj, Renaud F, Prugnolle F. Multiple independent introductions of Plasmodium falciparum in South America. Proc Natl Acad Sci U S A. 2012;109:511-6.

56. Fall B, Pascual A, Sarr FD, Wurtz N, Richard V, Baret E, Dieme Y, Briolant S, Bercion R, Wade B, Tall A, Pradines B. Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study. Malar J. 2013;12:107.

57. Pascual A, Fall B, Wurtz N, Fall M, Camara C, Nakoulima A, Baret E, Diatta B, Wade B, Briolant S, Pradines B. Plasmodium falciparum with multidrug resistance 1 gene duplications, Senegal. Emerg Infect Dis. 2013;19:814-5.

58. Ahmedou Salem Ms, Ndiaye M, Ouldabdallahi M, Lekweiry KM, Bogreau H, Konaté L, Faye B, Gaye O, Faye O, Mohamed Salem O Boukhary AO. Polymorphism of the merozoite surface protein-1 block 2 region in Plasmodium falciparum isolates from Mauritania. Malar J. 2014;13:26.

59. Djalle D, Njuimo Sp, Manirakisa A, Laganier R, Le Faou A, Rogier C. Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial. Malar J. 2014;13:9.

60. Madamet M, Fall B, Benoit N, Camara C, Amalvict R, Fall M, Dionne P, Fall B B, Nakoulima A, Diatta B, Dieme Y, Menard D, Wade B, Pradines B. Limited polymorphisms in K13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012-2013. Malar J. 2014;13:472.

61. Fall B, Camara C, Fall M, Nakoulima A, Dionne P, Diatta B, Dieme Y, Wade B, Pradines B. Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the malaria season 2013-2014. Malar J. 2015;14:60.

62. Boussaroque A, Fall B, Madamet M, Camara C, Benoit N, Fall M, Nakoulima A, Dionne P, Ba Fall K, Diatta B, Diémé Y, Wade B, Pradines B. Emergence of mutations in the K13 Propeller gene of Plasmodium falciparum isolates from Dakar, Senegal in 2013-2014. Antimicrob Agents Chemother. 2016;60:624-7.

63. Fall B, Madamet M, Camara C, Amalvict R, Fall M, Nakoulima A, Diatta B, Diémé Y, Wade B, Pradines B. Emergence of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine in Dakar, Senegal in 2014. Emerg Infect Dis. 2016;22:841-5.

64. Kesteman T, Randrianarivelojosia M, Raharimanga V, Randrianasolo L, Piola P, Rogier C. Effectiveness of malaria control interventions in Madagascar: a nationwide case-control survey. Malar J. 2016:15:83.

65. Kesteman T, Rafalimanantsoa SA, Razafimandimby H, Rasamimanana Hh, Raharimanga V, Ramarosandratana B, Ratsimbasoa A, Ratovonjato J, Elissa N, Randrianasolo L, Finlay A, Rogier C, Randrianarivelojosia M. Multiple causes of an unexpected malaria outbreak in a high-transmission area in Madagascar. Malar J. 2016;15:57.

66. Kesteman T, Randrianarivelojosia M, Piola P, Rogier C. Post-deployment effectiveness of malaria control interventions on Plasmodium falciparum infectons in Madagascar: a comprehensive phase IV assessment. Malar J. 2016;15:322.

67. Kesteman T, Randrianarivelojosia M, Mattern C, Raboanary E, Pourette D, Girond F, Raharimanga V, Randrianasolo L, Piola P, Rogier C. Nationwide evaluation of malaria infections, morbidity, mortality, and coverage of malaria control interventions in Madagascar. Malar J 2014;13:465.

68. Menard D, Khim N, Beghain J, Adegnika AA, Alam MS, Amodu O, Awab GR, Barnadas C, Berry A, Boum Y, Bustos MD, Cao J, Chen JH, Collet L, Cui L, Das Thakur G, Dieye A, Djalle D, Dorkenoo MA, Eboumbou Moukoko CE, Espino E, Fandeur T, Ferreira-Da-Cruz MF, Fola AA, Fuehrer HP, Hassan AM, Herrera S, Hongvanthong B, Houze S, Karim MJ, Jiang L, Kano S, Khan WA, Khanthavong M, Kremsner PG, Lacerda M, Leang R, Leelawong M, Li M, Lin K, Laminou IM, Mazarati JJ, Menard S, Morlais I, Muhindo Mavoko H, Musset L, Na-Bangchang K, Nambozi M, Niare K, Noedl H, Ouedraogo JB, Pillai DR, Pradines B, Quang Phuc B, Ramharter M, Randrianarivelojosia M, Sattabongkot J, Sheikh Omar R, Silue KD, Sirima SB, Sutherland C, Syafruddin D, Tahar R, Tang LH, Toure OA, Tshibangu P, Vigan-Womas I, Warsame M, Wini L, Zakeri S, Kim S, Eam R, Berne L, Khean C, Chy S, Ken M, Loch K, Canier L, Duru V, Legrand E, Barale JC, Stokes B, Straimer J, Witkowski B, Fidock Da, Rogier C, Ringwald P, Ariey F, Mercereau-Puijalon O.; for the K13 Artemisinin Resistance Multicenter Assessment consortium (KARMA). A worldwide map of Plasmodium falciparum artemisinin resistance. N Engl J Med. 2016;374:2453-64.

69. Boussaroque A, Fall B, Madamet M, Wade KA, Fall M, Nakoulima A, Fall KB, Dionne P, Benoit N, Diatta B, Diémé Y, Wade B, Pradines B. Prevalence of anti-malarial resistance genes in Dakar, Senegal from 2013 to 2014. Malar J. 2016;15:347.

 

Identification and development of new molecular markers of antimalarial resistance

70. Gaillard T, Briolant S, Houze S, Baragatti M, Wurtz N, Hubert V, Lavina M, Pascual A, Travaille C, Le Bras J, Pradines B. PftetQ and pfmdt copy numbers as predictive molecular markers of decreased ex vivo doxycycline susceptibility in imported Plasmodium falciparum malaria. Malar J. 2013;12:414.

71. Gaillard T, Fall B, Tall A, Wurtz N, Diatta B, Lavina M, Ba Fall K, Diene Sarr F, Baret E, Diémé Y, Wade B, Bercion R, Briolant S, Pradines B. Absence of association between ex vivo susceptibility to doxycycline and pftetQ and pfmdt copy numbers in Plasmodium falciparum isolates from Dakar, Senegal. Clin Microbiol Infect. 2012;18:E238-E240.

72. GaillardT, Sriprawat K, Briolant S, Wangsing C, Wurtz N, Baragatti M, Lavina M, Pascual A, Nosten F, Pradines B. Molecular markers and in vitro susceptibility to doxycycline in Plasmodium falciparum isolates from Thailand. Antimicrob Agents Chemother. 2015;59:5080-3.

73. Mura M, Briolant S, Donato D, Volney B, Pelleau S, Musset L, Legrand E. Absence of correlation between ex vivo susceptibility to doxycycline and pftetQ-pfmdt gene polymorphism in French Guiana. Malar J. 2015;14:286.

74. Gaillard T, Wurtz N, Houze S, Sriprawat K, Wansing C, Hubert V, Lebras J, Nosten F, Briolant S, Pradines B. Absence of association between Plasmodium falciparum small subunit ribosomal RNA gene mutations and in vitro decreased susceptibility to doxycycline. Malar J. 2015;14:348.

75. Gaillard T, Madamet M, Pradines B. Tetracyclines in malaria. Malar J. 2015;14:445.

76. Gaillard T, Dormoi J, Madamet M, Pradines B. Macrolides in malaria. Malar J. 2016;15:85.

77. Pascual A, Fall B, Wurtz N, Fall M, Camara A, Baret E, Diatta B, Ba Fall K, Mbaye PS, Dieme Y, Bercion R, Bogreau H, Briolant S, Rogier C, Wade B, Pradines B. In vitro susceptibility to quinine and microsatellite variations of the Plasmodium falciparum Na+/H+ exchanger transporter (Pfnhe-1) gene in 393 isolates from Dakar, Senegal. Malar J. 2013;12:189.

78. Pelleau S, Bertaux L, Briolant S, Ferdig MT, Sinou V, Pradines B, Parzy D, Jambou R. Differential association of Plasmodium falciparum Na+/H+ exchanger polymorphism and quinine responses in field- and culture-adapted isolates of Plasmodium falciparum. Antimicrob Agents Chemother. 2011;55:5834-41.

79. Briolant S, Pelleau S, Bogreau H, Hovette P, Zettor A, Castello J, Baret E, Amalvict R, Rogier C, Pradines B. In vitro susceptibility to quinine and microsatellite variations of the Plasmodium falciparum Na+/H+ exchanger (Pfnhe-1) gene: the absence of association in clinical isolates from the Republic of Congo. Malar J. 2011;10:37.

80. Deplaine G, Lavazec C, Bischoff E, Natalang O, Perrot S, Guillotte-Blisnick M, Coppée JY, Pradines B, Mercereau-Puijalon O, David PH. Artesunate tolerance in transgenic Plasmodium falciparum parasites overexpressing a tryptophan-rich protein. Antimicrob Agents Chemother. 2011;55:2576-84.

81. Briolant S, Bogreau H, Gil M, Bouchiba H, Baret E, Amalvict R, Rogier C, Pradines B. F423Y mutation in the pfmdr2 gene and the triple mutation (N51I, C59R, S108N) in pfdhfr gene are independently associated with pyrimethamine resistance in Plasmodium falciparum isolates. Antimicrob Agents Chemother. 2012;56:2750-2.

82. Wurtz N, Fall B, Pascual A, Fall M, Baret E, Camara C, Nakoulima A, Diatta B, Ba Fall K, Mbaye P S, Dieme Y, Bercion R, Wade B, Pradines B. Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine and dihydroartemisinin. Antimicrob Agents Chemother. 2014;58:7032-40.

83. Madamet M, Briolant S, AmalvictR, Benoit N, Bouchiba H, Cren J, Pradines B. The Plasmodium falciparum chloroquine resistance transporter is associated with ex vivo P. falciparum parasite response to pyronaridine. Parasit Vect. 2016;9:77.

84. Gendrot M, Fall B, Madamet M, Fall M, Wade Ka, Amalvict R, Nakoulima A, Benoit N, Diawara S, Diémé Y, Diatta B, Wade B, Pradines B. Absence of association between polymorphisms in the RING E3 ubuquitin-protein ligase gene and ex vivo susceptibility to conventional antimalarial drugs in Plasmodium falciparum isolates from Dakar, Senegal. Antimicrob Agents Chemother. 2016, accepted.

85. Andriantsoanirina V, Durand R, Pradines B, Baret E, Bouchier C, Ratsimbasoa A, Ménard D. In vitro susceptibility to pyrimethamine of DHFR I164L single mutant Plasmodium falciparum. Malar J. 2011;10:283.

86. Pascual A, Madamet M, Bertaux L, Amalvict R, Benoit N, Travers D, Cren J, Taudon N, Rogier C, Parzy D, Pradines B. In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene. Malar J. 2013;12:431.

 

Development of new antimalarial drugs (in vitro and in vivo) with evaluation and investigation of mode of action of new antimalarial drugs and mechanisms of resistance

87. Quirante J, Ruiz D, Gonzalez A, López C, Cascante M, Cortés R, Messeguer R, Calvis C, Baldomà L, Pascual A, Guérardel Y, Pradines B, Font-Bardía M, Calvet T, Biot C. Platinum(II) and palladium(II) complexes with (N,N') and (C,N,N')- ligands derived from pyrazole as anticancer and antimalarial agents: synthesis, characterization and in vitro activities. J Inorg Biochem. 2011;105:1720-8.

88. Yu XM, Ramiandrasoa F, Guetzoyan L, Pradines B, Quintino E, Gadelle D, Forterre P, Cresteil T, Mahy JP, Pethe S. Synthesis and biological evaluation of acridine derivatives as antimalarial agents. ChemMedChem. 2012;7:587-605.

89. Arabicia R, Biot C, Delanet G, Roussel P, Pascual A, Pradines B, Klahn H. Cyrhetrenyl chalcones : Synthesis, characterisation and antimalarial evaluation. J Organomet Chem. 2013;72:143-8.

90. Toro P, Klahn H, Pradines B, Lahoz F, Pascual A, Biot C, Arancibia R. Organometallic benzimidazoles: Synthesis, characterization and antimalarial activity. Inorg Chem Com. 2013;35:126-9.

91. Ibrahim N, Ibrahim H, Dormoi J, Briolant S, Pradines B, Moreno A, Mazier D, Legrand P, Nepveu F. Albumin-bound nanoparticles of practically water-insoluble antimalarial lead greatly enhance its efficacy. Int J Pharm. 2014;464:214-24.

92. Kumar K, Pradines B, Madamet M, Amalvict R, Kumar V. 1H-1,2,3-triazole tethered mono- and bis-ferrocenylchalcone-b-lactam conjugates: Synthesis and antimalarial evaluation. Eur J Med Chem. 2014;86:113-21.

93. Navarro M, Castro W, Madamet M, Amalvict R, Benoit N, Pradines B. Metal-chloroquine derivatives as possible anti-malarial drugs: evaluation of anti-malarial activity and mode of action. Malar J. 2014;13:471.

94. Kumar K, Pradines B, Madamet M, Amalvict R, Benoit N, Kumar V. 1H-1,2,3-triazole tethered isatin-ferrocene conjugates: Synthesis and in vitro antimalarial evaluation. Eur J Med Chem. 2014;87:801-4.

95. Mulie C, Taudon N, Desgrouas C, Jonet A, Pascual A, Agnamey P, Sonnet P. Enantiomerically pure amino-alcohol quinolines: in vitro anti-malarial activity in combination with dihydroartemisinin, cytotoxicity and in vivo efficacy in a Plasmodium berghei mouse model. Malar J. 2014;13:407.

96. Dubar F, Egan TJ, Pradines B, Kuter D, Ncokazi KK, Forge D, Paul JF, Pierrot C, Kalamou H, Khalife J, Buisine E, Rogier C, Vezin H, Forfar I, Slomianny C, Trivelli X, Kapishnikov S, Leiserowitz L, Dive D, Biot C. The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance. ACS Chem Biol. 2011;6:275-87.

97. Desgrouas C, Dormoi J, Chapus C, Ollivier E, Parzy D, Taudon N. In vitro and in vivo combination of cepharantine with anti-malarial drugs. Malar J. 2014;13:90.

98. Desgrouas C, Chapus C, Desplans J, Travaille C, Pascual A, Baghdikian B, Ollivier E, Parzy D, Taudon N. In vitro antiplasmodial activity of cepharanthine. Malar J. 2014;13:327.

99. Desgrouas C, Desbordes M, Dormoi J, Ollivier E, Parzy D, Taudon N. Quantitative analysis of cepharanthine in plasma based on semiautomatic microextraction by packed sorbent combined with liquid chromatography. J Anal Methods Chem. 2014;2014:695231.

100. Souraud JB, Briolant S, Dormoi J, Mosnier J, Savini H, Baret E, Amalvict R, Soulard R, Rogier C, Pradines B. Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model. Malar J. 2012;11:13.

101. Dormoi J, Briolant S, Desgrouas C, Pradines B. Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model. Malar J. 2013;12:127.

102. Dormoi J, Briolant S, Pascual A, Desgrouas C, Travaille C, Pradines B. Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model. Malar J. 2013;12:302.

103. Dormoi J, Savini H, Amalvict R, Baret E, Pradines B. In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum. Malar J. 2014;13:189.

104. Pascual A, Henry M, Briolant S, Charras S, Baret E, Amalvict R, Huyghues des Etages E, Feraud M, Rogier C, Pradines B. In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs. Antimicrob Agents Chemother. 2011;55:2472-4.

105. Dormoi J, Pascual A, Briolant S, Amalvict R, Charras S, Baret E, Huyghues Des Etages E, Feraud M, Pradines B. Proveblue (Methylene Blue): In Vitro Synergy in Combinational Therapy with Dihydroartemisinin. Antimicrob Agents Chemother. 2012;56:3467-9.

106. Dormoi J, Briolant S, Desgrouas C, Pradines B. Efficacy of Proveblue®, Methylene Blue, in an Experimental Cerebral Malaria Murine Model. Antimicrob Agents Chemother. 2013;57:3412-4.

107. Dormoi J, Pradines B. Dose responses of Proveblue Methylene Blue in an experimental murine cerebral malaria model. Antimicrob Agents Chemother. 2013;5: 4080-1.

 

Development of serological method based on antibody response against salivary proteins from vectors

108. Fontaine A, Pascual A, Orlandi-Pradines E, Diouf I, Remoué F, Pagès F, Fusaï T, Rogier C, Almeras L. Relationship between exposure to vector bites and antibody responses to mosquito salivary gland extracts. PLoS One. 2011;6:29107.

109. Fontaine A, Diouf I, Bakkali N, Missé D, Pagès F, Fusai T, Rogier C, Almeras L. Implication of haematophagous arthropod salivary proteins in host-vector interactions. Parasit Vectors. 2011;4:187.

110. Fontaine A, Pascual A, Diouf I, Bakkali N, Bourdon S, Fusai T, Rogier C, Almeras L. Mosquito salivary gland protein preservation in the field for immunological and biochemical analysis. Parasit Vectors. 2011;4:33.

111. Ali ZM, Bakli M, Fontaine A, Bakkali N, Vu Hai V, Audebert S, Boublik Y, Pagès F, Remoué F, Rogier C, Fraisier C, Almeras L. Assessment of Anopheles salivary antigens as individual exposure biomarkers to species-specific malaria vector bites. Malar J. 2012;31:11.

112. Fontaine A, Fusaï T, Briolant S, Buffet S, Villard C, Baudelet E, Pophillat M, Granjeaud S, Rogier C, Almeras L. Anopheles salivary gland proteomes from major malaria vectors. BMC Genomics. 2012;13:614.

113. Doucoure S, Mouchet F, Cournil A, Le Goff G, Cornelie S, Roca Y, Giraldez MG, Simon ZB, Loayza R, Misse D, Flores JV, Walter A, Rogier C, Herve JP, Remoue F. Human antibody response to Aedes aegypti saliva in an urban population in Bolivia: a new biomarker of exposure to Dengue vector bites. Am J Trop Med Hyg. 2012;87:504-10.

114. Drame PM, Machault V, Diallo A, Cornélie S, Poinsignon A, Lalou R, Sembène M, Dos Santos S, Rogier C, Pagès F, Le Hesran Jy, Remoué F. IgG responses to the gSG6-P1 salivary peptide for evaluating human exposure to Anopheles bites in urban areas of Dakar region, Sénégal. Malar J. 2012;11:72.

115. Vu Hai V., Pages F., Boulanger N., Audebert S., Parola P., Almeras L. Immunoproteomic identification of antigenic salivary biomarkers detected by Ixodes ricinus-exposed rabbit sera. Ticks Tick-borne Dis. 2013;4:459-68.

116. Sarr JB, Orlandi-Pradines E, Fortin S, Sow C, Cornelie S, Rogerie F, Guindo S, Konate L, Fusaï T, Riveau G, Rogier C, Remoue F. Assessment of exposure to Plasmodium falciparum transmission in a low endemicity area by using multiplex fluorescent microsphere-based serological assays. Parasit Vectors. 2011;4:212.

117. Vu Hai V, Almeras L, Socolovschi C, Raoult D, Parola P, Pages F. Monitoring human tic-borne disease risk and tick bite exposure in Europe: Available tools and promising future methods. Ticks Ticks Borne Dis. 2014;5:607-19.

 

Entomological investigations and evaluation of control strategies

118. Gadiaga L, Machault V, Pagès F, Gaye A, Jarjaval F, Godefroy L, Cissé B, Lacaux JP, Sokhna C, Trape JF, Rogier C. Conditions of malaria transmission in Dakar from 2007 to 2010. Malar J. 2011;10:312.

119. Vezenegho Sb, Adde A, Gaborit P, Carinci R, Issaly J, Pommier De Santi V, Dusfour I, Briolant S, Girod R. Mosquito Magnet® liberty plus trap baited with octenol confirmed best candidate for Anopheles surveillance and proved promising in predicting risk of malaria transmission in French Guiana. Malar J. 2014;13:384.

119. Vezenegho Sb, Carinci R, Gaborit P, Issaly J, Dusfour I, Briolant S, Girod R. Anopheles darlingi (Diptera: Culicidae) Dynamics in Relation to Meteorological Data in a Cattle Farm Located in the Coastal Region of French Guiana: Advantage of Mosquito Magnet Trap. Environ Entomol. 2015;44:454-62.

120. Trape JF, Tall A, Diagne N, Ndiath O, Ly AB, Faye J, Dieye-Ba F, Roucher C, Bouganali C, Badiane A, Sarr FD, Mazenot C, Touré-Baldé A, Raoult D, Druilhe P, Mercereau-Puijalon O, Rogier C, Sokhna C. Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. Lancet Infect Dis. 2011;11:925-32.

121. Corbel V, Akogbeto M, Damien GB, Djenontin A, Chandre F, Rogier C, Moiroux N, Chabi J, Banganna B, Padonou GG, Henry MC. Combination of malaria vector control interventions in pyrethroid resistance area in Benin: a cluster randomised controlled trial. Lancet Infect Dis. 2012;12:617-26.

122. Barikissou Damien G, Djenontin A, Chaffa E, Yamadjako S, Makhtar Drame P, Elanga Ndille E, Henry Mc, Corbel V, Remoué F, Rogier C. Effectiveness of insecticidal nets on uncomplicated clinical malaria: a case-ontrol study for operational evaluation. Malar J. 2016;15:102.

123. Ndiath MO, Cailleau A, Orlandi-Pradines E, Bessell P, Pagès F, Trape JF, Rogier C. Emerging knock-down resistance in Anopheles arabiensis populations of Dakar, Senegal: first evidence of a high prevalence of kdr-e mutation in West African urban area. Malar J. 2015;14:364.

124. Wotodjo AN, Trape JF, Richard V, Doucouré S, Diagne N, Tall A, Ndiath O, Faye N, Gaudart J, Rogier C, Sokhna C. No difference in the incidence of malaria in human-landing mosquito catch collectors and non-collectors in a Senegalese village with endemic malaria. PLoS One. 2015;10:0126187.

125. Randriamaherijaona S, Briet OJT, Boyer S, Bouraima A, N’Guessan R, Rogier C, Corbel V. Do holes in long-lasting insecticidal nets compromise their efficacy against pyrethoid resistant Anopheles gambiae and Culex quinquefasciatus? Results from a release-recapture study in experimental huts. Malar J. 2015;14:332.

Prediction of malaria transmission

126. Machault V, Vignolles C, Borchi F, Vounatsou P, Pages F, Briolant S, Lacaux JP, Rogier C. The use of remotely sensed environmental data in the study of malaria. Geospat Health. 2011;5:151-68.

127. Machault V, Vignolles C, Pages F, Gadiaga L, Tourre Ym, Gaye A, Sokhna C, Trape JF, Lacaux JP, Rogier C. Risk mapping of Anopheles gambiae SI densities using remotely-sensed environmental and meteorological data in a urban area : Dakar, Senegal. PLoS One. 2012;7:50674.

128. Texier G., Machault V., Barragati M., Boutin J. P, Rogier C. Environmental determinant of malaria cases among travellers. Malar J. 2013;12:87.

 

Compliance with antimalarial chemoprophylaxis and anti-vectorial protective measures

129. Sagui E, Resseguier N, Machault V, Ollivier L, Orlandi-Pradines E, Texier G, Pages F, Michel R, Pradines B, Briolant S, Buguet A, Tourette-Turgis C, Rogier C. Determinants of compliance with anti-vectorial protective measures among non-immune travellers during missions to tropical Africa. Malar J. 2011;10:232.

130. Creach MA, Velut G De Laval F, Briolant S, Aigle L, Marimoutou C, Deparis X, Meynard Jb, Pradines B, Simon F, Michel R, Mayet A. Factors associated with malaria chemoprophylaxis compliance among French service members deployed in Central African Republic. Malar J. 2016;15:174.

 

Surveillance of vector borne diseases in French Guiana

131. Epelboin L, Nacher M, Mahamat A, Pommier De Santi V, Berlioz-Arthaud A, Eldin C, Abboud P, Briolant S, Mosnier E, Do Socorro Mendoça Gomes M, Vreden SG, Pierre_Demar M, Lacerda M, Raoult D, Sampaio De Lemos ER, Djossou F. Q fever in French Guiana: Tip of the iceberg or epidemiological exception. PLoS Neglect Trop Dis. 2016;10:4598.

132. Adde A, Roucou P, Mangeas M, Ardillon V, Desenclos Jc, Rousset D, Girod R, Briolant S, Quenel P, Flamand C. Predicting dengue fever outbreaks in French Guiana using climate indicators. PLoS Neglect Trop Dis. 2016;10:4681.

133. De Laval F, Leparc-Goffart I, Meynard JB, Daubigny H, Simon F, Briolant S. Zika virus infections. Med Sante Trop. 2016;26:145-50.

 

Technical expertise

134. Fontaine A, Bourdon S, Belghazi M, Pophillat M, Fourquet P, Granjeaud S, Torrentino-Madamet M, Rogier C, Fusai T, Almeras L. Plasmodium falciparum infection-induced changes in erythrocyte membrane proteins. Parasitol Res. 2012;110:545-56.

135. Pascual A, Basco LK, Baret E, Amalvict R, Travers D, Rogier C, Pradines B. Use of the atmospheric generators for capnophilic bacteria Genbag-CO2 for the evaluation of in vitro Plasmodium falciparum susceptibility to standard anti-malarial drugs. Malar J. 2011;10:8.

136. Torrentino-Madamet M, Alméras L, Desplans J, Le Priol Y, Belghazi M, Pophillat M, Fourquet P, Jammes Y, Parzy D. Global response of Plasmodium falciparum to hyperoxia: a combined transcriptomic and proteomic approach. Malar J. 2011;10:4.

137. Fraisier C, Camoin L, Lim L, Bakli M, Belghazi M, Fourquet P, Granjeaud S, Osterhaus DME, Koraka P, Martina B, Almeras L. Altered protein networks and cellular pathways in severe West Nile disease in mice. PlosOne. 2013;8:68318.

138. Fraisier C, Rodrigues R, Vu Hai V, Belghazi M, Bourdon S, Paranhos-Baccala G, Camoin L, Almeras L, Peyrefitte CN. Hepatocyte pathway alterations in response to in vitro Crimean Congo hemorrh


© IHU Méditerranée Infection - Contact / Plan du site / Crédits